Video
Dr. Gupta on the role of immunotherapy as future standard of care for MIBC
Author(s):
“I think the audience would be encouraged to know that in the future, it seems like immunotherapy would become the standard of care,” says Shilpa Gupta, MD.
Video Player is loading.
In this video, Shilpa Gupta, MD, discusses the future research and takeaways associated with the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.
Related Videos
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Study data point to gender disparities in oncology research citations
Related Content
